# OnCo record cd33 (target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/targets/cd33/>
  a schema:BioChemEntity ;
  onco:kind "target" ;
  schema:identifier "cd33" ;
  schema:name "CD33"@en ;
  schema:description "CD33 is a myeloid surface marker on the blasts of 85 to 90% of acute myeloid leukaemias and on normal myeloid cells, so drugs against it also hit healthy marrow. It is the target of gemtuzumab ozogamicin, the first ADC ever approved (2000), withdrawn in 2010 and re-approved in 2017 at a lower fractionated dose."@en ;
  schema:url <https://onco.cc/targets/cd33/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/CD33>, <https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1659>, <https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000105383>, <https://www.uniprot.org/uniprotkb/P20138/entry>, <https://www.ncbi.nlm.nih.gov/gene/945> ;
  owl:sameAs <http://www.wikidata.org/entity/Q21114013> ;
  schema:citation <https://en.wikipedia.org/wiki/CD33> ;
  onco:tag "adc-target" ;
  schema:alternateName "CD33" ;
  onco:targetClass "surface-antigen" ;
  onco:firstDescribed "1988"^^xsd:gYear ;
  onco:related <https://onco.cc/biomarkers/cd33-expression/> ;
  onco:cancers <https://onco.cc/cancers/aml/> ;
  onco:drugs <https://onco.cc/drugs/gemtuzumab-ozogamicin/> ;
  onco:companies <https://onco.cc/companies/actinium-pharmaceuticals/>, <https://onco.cc/companies/orum-therapeutics/> .